- Home
- A-Z Publications
- Annual Review of Virology
- Previous Issues
- Volume 11, 2024
Annual Review of Virology - Volume 11, 2024
Volume 11, 2024
- Viral Vectors and Therapeutics
-
-
-
The Cold War and Phage Therapy: How Geopolitics Stalled Development of Viruses as Antibacterials
Vol. 11 (2024), pp. 381–393More LessThe bacteriolytic character of bacteriophages was employed as antibacterial therapy almost from the time of their discovery in 1917. In the United States, phage therapy was sporadic during the 1920s and 1930s but had dwindled into obscurity by the post-WWII period. This demise of phage therapy has traditionally been attributed to the superiority of antibiotics, discovered and first used during the war years, but this explanation is complicated by the fact that phage therapy outside the United States has had a longer and more successful life, especially in the countries of Eastern Europe. This review considers another, probably synergetic factor that was specific to the medical uses of phage in the United States: the geopolitical climate fostered by the Cold War reaction against Soviet science and its associated specter, socialized medicine. This analysis suggests that even such a purely scientific matter involving bacterial viruses cannot escape social forces and political ideologies.
-
-
-
-
Bacteriophage T4 as a Protein-Based, Adjuvant- and Needle-Free, Mucosal Pandemic Vaccine Design Platform
Vol. 11 (2024), pp. 395–420More LessThe COVID-19 pandemic has transformed vaccinology. Rapid deployment of mRNA vaccines has saved countless lives. However, these platforms have inherent limitations including lack of durability of immune responses and mucosal immunity, high cost, and thermal instability. These and uncertainties about the nature of future pandemics underscore the need for exploring next-generation vaccine platforms. Here, we present a novel protein-based, bacteriophage T4 platform for rapid design of efficacious vaccines against bacterial and viral pathogens. Full-length antigens can be displayed at high density on a 120 × 86 nm phage capsid through nonessential capsid binding proteins Soc and Hoc. Such nanoparticles, without any adjuvant, induce robust humoral, cellular, and mucosal responses when administered intranasally and confer sterilizing immunity. Combined with structural stability and ease of manufacture, T4 phage provides an excellent needle-free, mucosal pandemic vaccine platform and allows equitable vaccine access to low- and middle-income communities across the globe.
-